
|Videos|August 12, 2011
ASCO: Controversies in Phase I Clinical Trials
Author(s)Steve Joffe, MD
Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials.
Advertisement
Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials: how physicians should present these clinical trials to patients-phase I trials typically have very low response rates (5% to 10%)-and explain their purpose without exaggerating the likely results.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
2
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
3
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
4
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
5





















































